To include your compound in the COVID-19 Resource Center, submit it here.

FDA, EMA reviewing Shionogi's thrombocytopenia candidate

Shionogi & Co. Ltd. (Tokyo:4507) said FDA accepted and granted Priority

Read the full 117 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE